PRA Health Sciences Receives Recognition from Vaccine Industry Excellence (ViE)

RALEIGH, N.C., March 31, 2016 -- PRA Health Sciences (PRA) (NASDAQ:PRAH), is pleased to announce that it received a “Highly Commended” designation by Vaccine Industry Excellence (ViE) for Best Contract Research Organization. PRA was originally named a finalist in the category based on industry nominations. Finalists submitted a detailed questionnaire about their vaccine capabilities which was then blinded, reviewed, and rated by a panel of judges.

“This is a great honor,” said Frank Hijek, PRA Senior Vice President, Strategic Drug Development. “By combining PRA’s therapeutic expertise and experience with proven strategies and innovative approaches, we are redefining vaccine clinical research. This recognition speaks to our commitment to accelerate vaccine development.”

PRA’s vaccine experience includes Phase I - Phase IV adult and pediatric studies involving nearly 213,000 study participants at more than 3,000 sites around the world. In the past five years, PRA teams have participated in over 140 vaccine studies; these include studies that led to the approval of six vaccines that are currently on the market. More information about PRA’s Vaccine Solutions group can be found at www.pravaccinesolutions.com.

ABOUT PRA HEALTH SCIENCES

PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit www.prahs.com.

INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications
EMAIL: [email protected]  PHONE: +1 919.786.8463